切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2022, Vol. 10 ›› Issue (01) : 70 -74. doi: 10.3877/cma.j.issn.2095-5782.2022.01.013

综述

上腔静脉综合征的诊疗进展
刘超1, 丁鹏绪1, 周朋利1, 韩新巍1,()   
  1. 1. 450052 河南郑州,郑州大学第一附属医院介入科
  • 收稿日期:2021-04-29 出版日期:2022-02-25
  • 通信作者: 韩新巍

Recent progress in the diagonsis and treatment of superior vena cava syndrome

Chao Liu1, Pengxu Ding1, Pengli Zhou1, Xinwei Han1,()   

  1. 1. Department of Intervention, the First Affifiliated Hospital of Zhengzhou University, Henan Zhengzhou 450052, China
  • Received:2021-04-29 Published:2022-02-25
  • Corresponding author: Xinwei Han
引用本文:

刘超, 丁鹏绪, 周朋利, 韩新巍. 上腔静脉综合征的诊疗进展[J/OL]. 中华介入放射学电子杂志, 2022, 10(01): 70-74.

Chao Liu, Pengxu Ding, Pengli Zhou, Xinwei Han. Recent progress in the diagonsis and treatment of superior vena cava syndrome[J/OL]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(01): 70-74.

上腔静脉综合征是各种原因引起的完全或不完全性上腔静脉及其主要属支回流受阻所致的一组临床症候群,也是肿瘤科临床常见的急症。当患者出现急性或亚急性呼吸困难、面颈部肿胀,如不及时干预,进一步发展可导致缺氧、颅压增高,甚至死亡。随着时代变迁,上腔静脉综合征病因已发生很大变化,其诊断及治疗方法也随着医学技术的进步而发展。文章就上腔静脉综合征病因、临床表现、诊断及治疗做一综述。

Superior vena cava syndrome (SVCS) is a group of clinical symptoms caused by complete or incomplete obstruction of superior vena cava and its main branches. SVCS is a common tumor emergency. When the patient has acute or subacute dyspnea, face and neck swelling, if not timely intervention, can lead to hypoxia, increased intracranial pressure, and even death. With the change of the times, the etiologies of SVCS have changed greatly, and its diagnosis and treatment methods have also developed with the progress of medical technology. This article reviews the etiologies, clinical manifestations, diagnosis and treatments of SVCS to provide a better understanding.

表1 Stanford-Doty上腔静脉阻塞类型
表2 SVCS主要临床症状
表3 SVCS临床分级
[1]
Hunter W. The history of an aneurysm of the aorta with some remarkson aneurysms in general[J]. Med Obs Soc Phys Lond, 1757, 1: 323.
[2]
Klein-Weigel PF, Elitok S, Ruttloff A, et al. Superior vena cava syndrome[J]. Vasa 2020, 49(6): 437-448.
[3]
Bilyeu JA. Superior vena cava syndrome[J]. J Insur Med, 2001, 33: 349.
[4]
Herscovici R, Szyper-Kravitz M, Altman A, et al. Superior vena cava syndrome: changing etiology in the third millennium[J]. Lupus, 2012, 21: 93-96.
[5]
Uberoi R. Quality assurance guidelines for superior vena cava stenting in malignant disease[J]. Cardiovasc Intervent Radiol, 2006, 29: 319-322.
[6]
Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review[J]. Clin Oncol (R Coll Radiol), 2002, 14(5): 338-351.
[7]
Straka C, Ying J, Kong FM, et al. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome[J]. Springerplus, 2016, 5:229.
[8]
Friedman T, Quencer KB, Kishore SA, et al. Malignant venous obstruction: superior vena cava syndrome and beyond[J]. Semin Intervent Radiol, 2017, 34: 398-408.
[9]
Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features[J]. J Clin Oncol, 1993, 11(12): 2306-2313.
[10]
Ni R, Amr M, Kalla A. Hodgkin lymphoma-associated superior vena cava syndrome: a case of report and review of the literature[J]. Am J Case Rep, 2021, 22:e929437.
[11]
Arora Y, Carrillo RG. Lead-related superior vena cava syndrome: management and outcomes[J]. Heart Rhythm, 2021, 18(2):207-214.
[12]
Stanford W, Doty DB. The role of venography and surgery in the treatment of patients with superior vena cava obstruction[J]. Ann Thorac Surg, 1986, 41(2): 158-163.
[13]
Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology[J]. Medicine (Baltimore), 2006, 85(1): 37-42.
[14]
Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome--a proposed classification system and algorithm for management[J]. J Thorac Oncol, 2008, 3(8): 811-814.
[15]
Sheth S, Ebert MD, Fishman EK. Superior vena cava obstruction evaluation with MDCT[J]. Am J Roentgenol, 2010, 194(9): W345-W346.
[16]
Kim HC, Chung SH, Park SH, et al. Systemic to pulmonary vena shunt in superior vena cava obstruction: depiction on computed tomography venography[J]. Acta Radiol, 2004, 45(3): 269-274.
[17]
Yoel S, Erica S. Prevalence and etiology of focal liver opacification in patients with superior vena cava obstruction[J].J Comput Assist Tomogr, 2013, 37: 805-808.
[18]
Loeffler JS, Leopold KA, Recht A, et al. Emergency prebiopsy radiation for mediastinal masses: impact on subsequent pathologic diagnosis and outcome[J]. J Clin Oncol, 1986, 4(5): 716-721.
[19]
Koegelenberg CF, Bolliger CT, Plekker DP, et al. Diagnostic yield and safety of ultrasound-assisted biopsies in superior vena cava syndrome[J]. Eur Respir J, 2009, 33: 1389-1395.
[20]
Pop D, Venissac N, Nadeemy AS, et al. Video-assisted mediastinoscopy in superior vena cava obstruction: to fear or not to fear?[J]. J Thorac Oncol, 2012, 7(2): 386-389.
[21]
Zimmerman S, Davis M. Rapid fire: superior vena cava syndrome[J]. Emerg Med Clin North Am, 2018, 36: 577-584.
[22]
Gloviczki P, Pairolero P, McKusick M, et al. Surgical treatment of superior vena cava syndrome//Gloviczki P, Yao J, eds. Handbook of venous disorders (2nd ed)[M]. London: Arnold; 2001: 408-417.
[23]
熊刚, 杨康, 廖克龙, 等. 血管切除重建治疗癌性上腔静脉综合征[J]. 第三军医大学学报, 2005, 27(24): 2450-2452.
[24]
Ahmann FR. A reassessment of the clinical implications of the superior vena caval syndrome[J]. J Clin Oncol, 1984, 2:961-969.
[25]
Nicholson AA, Ettles DF, Arnold A, et al. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy[J]. J Vasc Interv Radiol, 1997, 8(5): 781-788.
[26]
Sato Y, Inaba Y, Yamaura H, et al. Malignant inferior vena cava syndrome and congestive hepatic failure treated by venous stent placement[J]. J Vasc Interv Radiol, 2012, 23(10): 1377-1380.
[27]
Van Putten JW, Schlosser NJ, Vujaskovic Z, et al. Superior vena cava obstruction caused by radiation induced venous fibrosis[J]. Thorax, 2000, 55(3): 245-246.
[28]
Pereira JR, Martins CJ, Ikari FK, et al. Neoadjuvant chemotherapy vs. radiotherapy alone for superior vena cava syndrome (SVCS) due to non-small cell lung cancer (NSCLC): preliminary results ofa randomized phase II trial[J]. Eur J Cancer, 1999, 35(Suppl 4): 260.
[29]
Scalese MJ, Hayes SL, Lott S. Antithrombotic therapy post endovascular stenting for superior vena cava syndrome[J]. Hosp Pharm, 2017, 52(10): 666.
[30]
Haddad MM, Thompson SM, McPhail IR, et al. Is long-term anticoagulation required after stent placement for benign superior vena cava syndrome?[J]. J Vasc Interv Radiol, 2018, 29(12):1741-1747.
[31]
Kalra M, Sen I, Gloviczki P. Endovenous and operative treatment of superior vena cava syndrome[J]. Surg Clin North Am, 2018, 98(2): 321-335.
[32]
Wei S, Liu J, Li X, et al. A retrospective stenting study on superior vena cava syndrome caused by lung cancer[J]. Thorac Cancer, 2020, 11(7): 1835-1839.
[33]
Straka C, Ying J, Kong FM, et al. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome[J]. Springerplus, 2016, 5: 229.
[34]
Matthaiou N, Galanakis N, Kehagias E, et al. Endovascular treatment of malignant superior vena cava syndrome through upper-limb access: a comparison between venous-dedicated and conventional stents[J].J Vasc Interv Radiol, 2020, 31(12): 2066-2072.
[35]
Fagedet D, Thony F, Timsit JF, et al. Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy[J]. Cardiovasc Intervent Radiol, 2013, 36: 140-149.
[36]
Da Ines D, Chabrot P, Motreff P, et al. Cardiac tamponade after malignant superior vena cava stenting: two case reports and brief review of the literature[J]. Acta Radiol, 2010, 51: 256-259.
[37]
Siani A, Marcucci G, Accrocca F, et al. Endovascular central venous stenosis treatment ended with superior vena cava perforation, pericardial tamponade, and exitus[J]. Ann Vasc Surg, 2012, 26: 733.e9-12.
[38]
Martin M, Baumgartner I, Kolb M, et al. Fatal pericardial tamponade after Wallstent implantation for malignant superior vena cava syndrome[J]. J Endovasc Ther, 2002, 9: 680-684.
[39]
Sun K, Batra R, Markin NW, et al. Transesophageal echocardiogram-guided stent placement in superior vena cava syndrome secondary to granulomatous lung disease: a case series and literature review[J]. Vasc Endovascular Surg, 2017, 51(8): 562-566.
[1] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[2] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[3] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[4] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[5] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[6] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[7] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[8] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[9] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[10] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[13] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[14] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[15] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?